Preview

Obesity and metabolism

Advanced search

The gravicentric Concept in type 2 Diabetes: practical implementation

https://doi.org/10.14341/2071-8713-3865

Abstract

The epidemic rise of patients with type 2 diabetes mellitus (T2DM) worldwide continues, despite all efforts taken by the international medical community to curb it. It seems that the advent of new drugs does not contribute to a better control of the disease, the tightening up of diagnostic criteria causes an abrupt increase in the number of patients, while a revision of the main goals of treatment (a reduction of targets for glycemic control) often becomes an argument in favor of an overly aggressive approach to drug therapy in diabetes. The main therapeutic goal of existing algorithms for the management of T2DM patients is to achieve and maintain long-term indicators of glycemic control, as close to normal values as possible. However, almost none of these algorithms address the factors associated with the pathogenesis of development and progression of the underlying disease, such as lack of exercise and excessive adiposity. For the sake of achieving glycemic target values, patients often receive treatment that is known to be conducive to weight gain, insulin resistance and increased progression of relative insulin deficiency, eventually leading to the prescription of exogenous insulin. At the same time, an active modification of the pathogenetic factors of T2DM – excess body weight and physical inactivity – may lead to restoration of glucose tolerance, reducing the need of pharmacotherapy until its complete withdrawal, as has been shown in many major studies [2]. The "gravicentric concept" of treatment of T2DM is designed to redefine the basic therapeutic targets and change the emphasis in the of patients' management scheme. Its mission is to create a clear idea for both doctors and patients about the possibility of de-intensification of pharmacotherapy under certain conditions, and to focus maximum effort to address the factors of progression of the disease with the hope of a cure or remission

About the Authors

Sh Levit

glava Instituta diabeta i endokrinologii, Meditsinskiy tsentr Assuta, Tel'-Aviv, Izrail'.


L Dzeranova

glavnyy nauchnyy sotrudnik otdeleniya neyroendokrinologii i osteopatiy Instituta klinicheskoy endokrinologii, FGBU Endokrinologicheskiy nauchnyy tsentr Minzdrava RF


Yu Philippov

Nauchnyy sotrudnik otdeleniya programmnogo obucheniya i lecheniya Instituta diabeta, FGBU Endokrinologicheskiy nauchnyy tsentr Minzdrava RF


References

1. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocrine Practice. 2013 Mar-Apr;19(2):327-336.

2. Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012 Dec 19;308(23):2489-2496. DOI: http://dx.doi.org/10.1001/jama.2012.67929

3. Eckel RH, Committee FtN. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1997 November 4, 1997;96(9):3248-3250. DOI: http://dx.doi.org/10.1161/01.cir.96.9.3248

4. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. DOI: http://dx.doi.org/10.1161/CIRCULATIONAHA.106.171016

5. Frellick M. AMA Declares Obesity a Disease: Medscape; 2013 [09.09.2013]. Available from: http://www.medscape.com/viewarticle/806566

6. Levit S, Philippov YI, Gorelyshev AS. Type 2 Diabetes Mellitus: time to change the concept. Diabetes Mellitus. 2013 (1):91-102.

7. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 Aug;49(8):1711-1721. DOI: http://dx.doi.org/10.1007/s00125-006-0316-2

8. Levit S, Toledano Y, Wainstein J. Improved glycaemic control with reduced hypoglycaemic episodes and without weight gain using long-term modern premixed insulins in type 2 diabetes. International Journal of Clinical Practice. 2011 Feb;65(2):165-171. DOI: http://dx.doi.org/10.1111/j.1742-1241.2010.02513.x

9. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E. Induction of Long-Term Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients by Transient Intensive Insulin Treatment. Diabetes Care. 1997 September 1, 1997;20(9):1353-1356. DOI: http://dx.doi.org/10.2337/diacare.20.9.1353

10. El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet M, Leverve X. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I. Journal of Biological Chemistry. 2000 January 7, 2000;275(1):223-228. DOI: http://dx.doi.org/10.1074/jbc.275.1.223

11. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochemical Journal. 2000 Jun 15, 2000;348(3):607-614. DOI: http://dx.doi.org/10.1042/0264-6021:3480607

12. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. Journal of Clinical Investigation. 2010 Jul;120(7):2355-2369. DOI: http://dx.doi.org/10.1172/JCI40671


Review

For citations:


 ,  ,   The gravicentric Concept in type 2 Diabetes: practical implementation. Obesity and metabolism. 2013;10(3):50-54. https://doi.org/10.14341/2071-8713-3865

Views: 1217


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)